CD19 and B-cell chronic lymphocytic leukemia: Cord blood-derived anti-CD19 CAR NK cells showed good activity towards CLL cells in vitro, and preliminary evidences from a clinical trial have already demonstrated the safety and efficacy of this approach in patients with CD19-positive tumors, including CLL (274, 281).